NEW YORK, Sept. 25, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
PCR 2012: A Focus on Sales Growth
http://www.reportlinker.com/p0980750/PCR-2012-A-Focus-on-Sales-Growth.ht...
Background
From its development in the 1980s, Polymerase Chain Reaction (PCR) has become a commonly used and indispensable technique in the research setting, as well as in the clinic. The PCR market is expected to grow to over $38 billion by 2015, at an annual growth rate of over 10%. However markets are also changing as new applications are developed and new instruments are launched. Today, more than ever, developers and vendors in this field are targeting their resources in those areas that best support their own sales and growth strategies.
Purpose
This report, based on an analysis of prevailing and emerging market conditions in the PCR field. has been produced to assist marketing and sales, and the identification of new opportunities. It is the outcome of an extensive global study involving more than 600 experienced PCR users. It's findings provide a "focus on sales growth" to developers and vendors in the PCR field, and the changes that are driving these developments.
Analysis
As part of this report, market areas outlined below have been analysed to provide information relevant to marketing and sales, new market opportunities, qualified sales leads, customer needs and future plans, competitive position, new and emerging applications, growing and declining areas and threats.
Download brochure
Market Areas
• Routine use: Use of PCR by end-users for running routine (developed and validated) PCR tests, the development or validation of PCR tests and for the qualitative discovery using PCR methods
• Companies: Purchases of PCR and related systems by end-users from more than 25 companies and anticipated PCR purchases by end-users from more than 25 companies over the next three years, each ranked according to their competitive position.
• PCR Methods: Current use of more than 30 PCR techniques by end-users and the anticipated use of these techniques by end-users over the next three years, each ranked according to their competitive position.
• PCR Application: Current use of 12 leading PCR applications by end-users and the anticipated use of these applications by end-users over the next three years, each ranked according to their competitive position.
• Preferred Companies: End-users' preferred companies in the PCR field, each ranked according to their competitive position.
• Products: End-users' preferred products (and associated companies) in the PCR field, each ranked according to their competitive position.
• Strengths: End-users' disclosures of the strengths of their preferred products in the PCR field, each ranked according to their competitive position.
• Weaknesses: End-users' disclosures of the weaknesses of their preferred products in the PCR field, each ranked according to their relative position.
• Current Financial Budgets: End-users' annual financial budgets for PCR studies.
• Current Budget Breakdown: The breakdown of end-users' PCR financial budgets in eight key areas, relating to their current expenditure on PCR products and activities.
• Future Budget Breakdown: The breakdown of end-users' PCR financial budgets in eight key areas, relating to their anticipated expenditure over the next three years, on PCR products and activities.
• Future Financial Budgets: End-users' anticipated changes (percentage increases or decrease) over the next three years, relating to their PCR activities
• Consumables: End-users' top three consumables, associated with their PCR activities.
• Quality Control Guidelines: End-users' adherence to established quality control guidelines or procedures, relating to the conduct of PCR studies.
• Current Challenges: End-users' disclosures on molecular types that present the greatest technical challenges to PCR analysis, together with the associated sample types (matrices), associated PCR methods and underlying reasons.
• Innovation: End-users' current needs relating to 12 key areas of required innovation in the PCR field, each ranked (on a scale of 1 to 10) according to their importance.
• Recent Innovations: End-users disclosures on the most important innovations relating to their use of PCR, over the last three years.
• Future Innovation: End-users' disclosures on what they anticipate will be the most important innovations in the PCR field, over the next three years.
• Biomarkers: End-users' application of PCR methods for the study of disease biomarkers, including molecular types and their clinical utilities.
• Organisations: End-users organisations include clinics or hospitals, government bodies, large international companies, research institutes, small and medium sized companies, universities and veterinary centres.
• Fields: End-users underlying fields include biotechnology, chemicals, clinical or hospital, defence, energy, environmental, food and drink, forensics, geology, government, healthcare, natural products, pharmaceuticals, research institutes, security and universities.
• Bioinformatics Software: End-users' disclosures on their preferred bioinformatics software, associated with PCR studies.
• Purpose: End-users' underlying reasons for using PCR analysis across 13 major fields (biotechnology, chemicals, clinical or hospital, defence, energy, environmental, food and drink, forensics, geology, government, healthcare, natural products, pharmaceuticals, research institutes, security, university), each ranked according to their relative importance.
• Study Samples: Study sample types analysed by end-users using PCR methods, each ranked according to their relative importance.
• Sample Preparation: The use of sample preparation methods by end-users for PCR studies, each ranked according to their importance.
Chapter 1 Introduction
Chapter 2 Study Participants
2.1 This Chapter
2.2 Countries
2.3 Regions
2.4 Organisation Types
2.5 Fields
2.6 PCR Types
2.7 Participants
2.8 Discussion
Figure 2.1 Countries of individuals who participated in PCR 2012
Figure 2.2 Global regions of individuals who participated in PCR 2012.
Figure 2.3 Organisation types of individuals who participated in PCR 2012
Figure 2.4 Fields of individuals who participated in PCR 2012
Table 2.1 Countries of individuals who participated in PCR 2012
Table 2.2 Global regions of individuals who participated in PCR 2012
Table 2.3 Organisation types of individuals who participated in PCR 2012
Chapter 3 PCR Techniques
3.1 This Chapter
3.2 Current Techniques
3.3 Future Techniques
3.4 Discussion
Figure 3.1 Top ten currently used PCR techniques, indicated by individuals who participated in PCR 2012
Table 3.1 Currently used PCR techniques, indicated by individuals who participated in PCR 2012
Figure 3.2 Other currently used PCR techniques, indicated by individuals who participated in PCR 2012
Table 3.2 Other currently used PCR techniques, indicated by individuals who participated in PCR 2012
Figure 3.3 Top ten PCR techniques that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in PCR 2012
Table 3.3 PCR techniques that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in PCR 2012
Figure 3.4 Other PCR techniques that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in PCR 2012
Table 3.4 Other PCR techniques that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated PCR 2012
Chapter 4 PCR Applications
4.1 This Chapter
4.2 Current Applications
4.3 Future Applications
4.4 Discussion
Figure 4.1 Top ten currently used PCR applications, indicated by individuals who participated in PCR 2012
Table 4.1 Currently used PCR applications, indicated by individuals who participated in PCR 2012
Figure 4.2 Other currently used PCR applications, indicated by individuals who participated in PCR 2012
Table 4.2 Other currently used PCR applications, indicated by individuals who participated in PCR 2012
Figure 4.3 Top ten PCR applications that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in PCR 2012
Table 4.3 PCR applications that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in PCR 2012
Figure 4.4 Other PCR applications that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in PCR 2012
Table 4.4 Other PCR applications that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in PCR 2012
Chapter 5 Companies
5.1 This Chapter
5.2 Current Companies
5.3 Future Companies
5.4 Discussion
Figure 5.1 Top ten PCR company suppliers, currently used by individuals who participated in PCR 2012
Table 5.1 PCR company suppliers, currently used by individuals who participated in PCR 2012
Figure 5.2 Other PCR company suppliers, currently used by individuals who participated in PCR 2012
Table 5.2 Other PCR company suppliers, currently used by individuals who participated in PCR 2012
Figure 5.3 Top ten PCR company suppliers that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in PCR 2012
Table 5.3 PCR company suppliers that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in PCR 2012
Figure 5.4 Other PCR company suppliers that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in PCR 2012
Table 5.4 Other PCR company suppliers that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in PCR 2012
Chapter 6 Preferred Companies and Products
6.1 This Chapter
6.2 Current Methods
6.3 Future Methods
6.4 Strengths
6.5 Weaknesses
6.6 Discussion
Figure 6.1 Top ten preferred suppliers in the PCR field, indicated by individuals who participated in PCR 2012
Table 6.1 Preferred suppliers in the PCR field, indicated by individuals who participated in PCR 2012
Figure 6.2 Other preferred suppliers in the PCR field, indicated by individuals who participated in PCR 2012
Table 6.2 Other preferred suppliers in the PCR field, indicated by individuals who participated in PCR 2012
Figure 6.3 Top ten preferred products in the PCR field, indicated by individuals who participated in PCR 2012
Table 6.3 Preferred products in the PCR field, indicated by individuals who participated in PCR 2012
Figure 6.4 Other preferred products in the PCR field, indicated by individuals who participated in PCR 2012
Table 6.4 Other Top preferred products in the PCR field, indicated by individuals who participated in PCR 2012
Figure 6.5 Top ten strengths of preferred products in the PCR field, indicated by individuals who participated in PCR 2012
Table 6.5 Strengths of preferred products in the PCR field, indicated by individuals who participated in PCR 2012
Figure 6.6 Other strengths of preferred products in the PCR field, indicated by individuals who participated in PCR 2012
Table 6.6 Other strengths of preferred products in the PCR field, indicated by individuals who participated in PCR 2012
Figure 6.7 Top ten weaknesses of preferred products in the PCR field, indicated by individuals who participated in PCR 2012
Table 6.7 Weaknesses of preferred products in the PCR field, indicated by individuals who participated in PCR 2012
Figure 6.8 Other weaknesses of preferred products in the PCR field, indicated by individuals who participated in PCR 2012
Table 6.8 Other weaknesses of preferred products in the PCR field, indicated by individuals who participated in PCR 2012
Chapter 7 PCR Expenditure and Budgets
7.1 This Chapter
7.2 Financial budget
7.3 Future Methods
7.4 Strengths
7.5 Weaknesses
7.6 Discussion
Figure 7.1 Annual financial budgets for PCR studies, indicated by individuals who participated in PCR 2012
Table 7.1 Annual financial budgets for PCR studies, indicated by individuals who participated in PCR 2012
Figure 7.2 The breakdown of current financial budgets for PCR studies, indicated by individuals who participated in PCR 2012
Table 7.2 The breakdown of current financial budgets for PCR studies, indicated by individuals who participated in PCR 2012
Figure 7.3 The anticipated future breakdown of financial budgets (over the next three years, 2012 to 2015) for PCR studies, indicated by individuals who participated in PCR 2012
Table 7.3 The anticipated future breakdown of financial budgets (over the next three years, 2012 to 2015) for PCR studies, indicated by individuals who participated in PCR 2012
Chapter 8 Purpose of PCR Use
8.1 This Chapter
8.2 Purpose
8.3 Discussion
Figure 8.1 Top ten reasons for using PCR in the biotechnology industry, indicated by individuals who participated in PCR 2012
Figure 8.2 Top ten reasons for using PCR in the Chemicals industry, indicated by individuals who participated in PCR 2012
Figure 8.3 Top ten reasons for using PCR in clinics or hospitals, indicated by individuals who participated in PCR 2012
Figure 8.4 Top ten reasons for using PCR in the environmental industry, indicated by individuals who participated in PCR 2012
Figure 8.5 Top ten reasons for using PCR in the food and drink industry, indicated by individuals who participated in PCR 2012
Figure 8.6 Top ten reasons for using PCR in the forensics industry, indicated by individuals who participated in PCR 2012
Figure 8.7 Top ten reasons for using PCR in the Government organisations, indicated by individuals who participated in PCR 2012
Figure 8.8 Top ten reasons for using PCR in the healthcare industry, indicated by individuals who participated in PCR 2012
Figure 8.9 Top ten reasons for using PCR in the pharmaceutical industry, indicated by individuals who participated in PCR 2012
Figure 8.10 Top ten reasons for using PCR in research institutes, indicated by individuals who participated in PCR 2012
Figure 8.11 Top ten reasons for using PCR in universities, indicated by individuals who participated in PCR 2012
Chapter 9 Samples
9.1 This Chapter
9.2 Purpose
9.3 Discussion
Figure 9.1 Top ten sample types analysed using DNA PCR, indicated by individuals who participated in PCR 2012
Table 9.1 Sample types analysed using PCR, indicated by individuals who participated in PCR 2012
Chapter 10 Sample Preparation
10.1 This Chapter
10.2 Sample Preparation
10.3 Discussion
Figure 10.1 Top sample preparation methods of DNA PCR users who participated in PCR 2012
Table 10.1 Sample preparation methods of PCR users who participated in PCR 2012
Figure 10.2 Other sample preparation methods of DNA PCR users who participated in PCR 2012
Table 10.2 Other sample preparation methods of DNA PCR users who participated in PCR 2012
Chapter 11 Therapeutic Areas
11.1 This Chapter
11.2 Therapeutic Areas
11.3 Discussion
Figure 11.1 Top ten therapeutic areas of PCR users who participated in PCR 2012
Table 11.1 Therapeutic areas of PCR users who participated in PCR 2012
Figure 11.2 Other therapeutic areas of PCR users who participated in PCR 2012
Table 11.2 Other therapeutic areas of PCR users who participated in PCR 2012
Chapter 12 Disease Biomarkers
12.1 This Chapter
12.2 Use of PCR
12.3 Biomarker Types
12.4 Clinical Utility
12.5 Discussion
Figure 12.1 The use of PCR for the study of disease biomarkers, indicated by individuals who participated in PCR 2012
Figure 12.2 Principal disease biomarkers studied using PCR, indicated by individuals who participated in PCR 2012
Table 12.1 Other disease biomarkers studied using PCR, indicated by individuals who participated in PCR 2012
Figure 12.3 Clinical utilities of disease biomarkers studied using PCR, indicated by individuals who participated in PCR 2012
Table 12.2 Other clinical utilities of disease biomarkers studied using PCR, indicated by individuals who participated in PCR 2012
Chapter 13 Bioinformatics Software
13.1 This Chapter
13.2 Bioinformatics Software
13.3 Discussion
Figure 13.1 Top ten bioinformatics software system used for PCR, indicated by users who participated in PCR 2012
Table 13.1 Bioinformatics software system used for DNA PCR, indicated by users who participated in PCR 2012
Figure 13.2 Other bioinformatics software system used for PCR, indicated by users who participated in PCR 2012
Table 13.2 Other bioinformatics software system used for PCR, indicated by users who participated in PCR 2012
Chapter 14 Challenging Applications
14.1 This Chapter
14.2 Most challenging Molecules
14.3 Most challenging sample types (matrices)
14.4 PCR methods used
14.5 Underlying reasons
14.6 Discussion
Figure 14.1 The most challenging molecules studies using PCR, indicated by users who participated in PCR 2012
Table 14.1 The most challenging molecules studies using PCR, indicated by users who participated in PCR 2012
Figure 14.2 The most challenging sample types (matrices) studies using PCR, indicated by users who participated in PCR 2012
Table 14.2 The most challenging sample types (matrices) studies using PCR, indicated by users who participated in PCR 2012
Figure 14.3 Top ten PCRs methods used with the most challenging molecules studies using PCR, indicated by users who participated in PCR 2012
Table 14.3 PCRs methods used with the most challenging molecules studies using PCR, indicated by users who participated in PCR 2012
Figure 14.4 Top ten underlying reasons for the challenges encountered using PCR analysis, indicated by users who participated in PCR 2012
Table 14.4 Underlying reasons for the challenges encountered using PCR analysis, indicated by users who participated in PCR 2012
Chapter 15 Innovation
15.1 This Chapter
15.2 Required Innovation
15.3 Recent Innovation
15.4 Future Innovation
15.5 Discussion
Figure 15.1 Top ten most required areas of innovation in PCR, indicated by individuals who participated in PCR 2012
Table 15.1 Most required areas of innovation in PCR, indicated by individuals who participated in PCR 2012
Figure 15.2 Other required areas of innovation in PCR, indicated by individuals who participated in PCR 2012
Table 15.2 Other required areas of innovation in PCR, indicated by individuals who participated in PCR 2012
Figure 15.3 Top ten recent innovations (in the last three years) in PCR, indicated by individuals who participated in PCR 2012
Table 15.3 Recent innovations (in the last three years) in PCR, indicated by individuals who participated in PCR 2012
Figure 15.4 Top ten future anticipated innovations (in the next three years) in PCR, indicated by individuals who participated in PCR 2012
Table 15.4 Future anticipated innovations (in the next three years) in PCR, indicated by individuals who participated in PCR 2012
Chapter 16 Quality Control
16.1 This Chapter
16.2 Quality Control
16.3 Future Innovation
16.4 Discussion
Figure 16.1 Top ten most commonly used quality control guidelines or procedures used in PCR analysis, indicated by individuals who participated in PCR 2012
Table 16.1 Quality control guidelines or procedures used in PCR analysis, indicated by individuals who participated in PCR 2012
Chapter 17 Discussion
Appendix 1
To order this report:
Genomics Industry: PCR 2012: A Focus on Sales Growth
Contact Nicolas: nicolasbombourg@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
